Meeting
2023 ASCO Genitourinary Cancers Symposium
Evaluation of eligibility criteria in contemporary renal cell carcinoma based on ASCO-FCR recommendations.
Authors
Sweta R. Prajapati
City of Hope Comprehensive Cancer Center, Duarte, CA
Sweta R. Prajapati , Matthew I. Feng , Daniela V. Castro , Kyle O. Lee , Elyse H. Chan , Ishaan Sehgal , Jalen Patel , Anna O'Dell , Zeynep Busra Zengin , Xiaochen Li , Alex Chehrazi-Raffle , Nazli Dizman , Abhishek Tripathi , Sandy Liu , Benjamin D. Mercier , Luis A Meza , Errol James Philip , Tanya B. Dorff , Sumanta Monty Pal , Adam Rock
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Cancer Disparities
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 612)
DOI
10.1200/JCO.2023.41.6_suppl.612
Abstract #
612
Poster Bd #
E2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
Explainable machine learning to inform real-world evidence: A case study on small cell lung cancer survival analysis.
First Author: Luca Marzano
Poster
2023 ASCO Genitourinary Cancers Symposium
Evaluation of eligibility criteria in advanced prostate cancer clinical trials based on ASCO-FCR recommendations.
First Author: Matthew I. Feng
Poster
2023 ASCO Genitourinary Cancers Symposium
Local and systemic therapies for renal cell carcinoma with brain metastases: A single-institution series.
First Author: Teja Ganta
Poster
2021 ASCO Annual Meeting
Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and brain metastases: results from the CheckMate 920 trial.
First Author: Hamid Emamekhoo